الفهرسة نشطة
للباحثين للناشرين تسجيل الدخول إنشاء حساب
الرئيسية المؤلفون Ehab M. Khalil
EK

Ehab M. Khalil

h-7 H-Index
63 Citations
7 Papers

Published Papers

7 indexed
1
Treatment results of pediatric nasopharyngeal carcinoma, NCI, Cairo University experience
Journal of the Egyptian National Cancer Institute Q1 2015 10.1016/j.jnci.2015.06.004
11 citations 379
2
Treatment results of pediatric nasopharyngeal carcinoma, NCI, Cairo University experience
Journal of the Egyptian National Cancer Institute Q1 2015 10.1016/j.jnci.2015.06.004
11 citations 379
3
Volumetric-modulated arc therapy (VMAT) versus 3D-conformal radiation therapy in supra-diaphragmatic Hodgkin’s Lymphoma with mediastinal involvement: A dosimetric comparison
Journal of the Egyptian National Cancer Institute Q1 2016 10.1016/j.jnci.2016.04.007
10 citations 383
4
Volumetric-modulated arc therapy (VMAT) versus 3D-conformal radiation therapy in supra-diaphragmatic Hodgkin’s Lymphoma with mediastinal involvement: A dosimetric comparison
Journal of the Egyptian National Cancer Institute Q1 2016 10.1016/j.jnci.2016.04.007
10 citations 381
5
Hypofractionated Volumetric Modulated Arc Radiotherapy with simultaneous Elective Nodal Irradiation is feasible in prostate cancer patients: A single institution experience
Journal of the Egyptian National Cancer Institute Q1 2016 10.1016/j.jnci.2016.04.001
7 citations 380
6
Hypofractionated Volumetric Modulated Arc Radiotherapy with simultaneous Elective Nodal Irradiation is feasible in prostate cancer patients: A single institution experience
Journal of the Egyptian National Cancer Institute Q1 2016 10.1016/j.jnci.2016.04.001
7 citations 381
7
Low-dose fractionated radiation with induction docetaxel and cisplatin followed by concurrent cisplatin and radiation therapy in locally advanced nasopharyngeal cancer
Hematology/Oncology and Stem Cell Therapy Q3 2021 10.1016/j.hemonc.2020.05.005
7 citations 384

Publication Activity

Journals Published In

Journal of the Egyptian National Cancer Institute
🇪🇬 Q1 AMS 94
Hematology/Oncology and Stem Cell Therapy
🇸🇦 Q3 AMS 72